強皮症治療薬の世界市場2017-2021

Technavioが出版した調査資料(IRTNTR13556)
◆英語タイトル:Global Scleroderma Treatment Market 2017-2021
◆商品コード:IRTNTR13556
◆発行会社(調査会社):Technavio
◆発行日:2017年6月28日
◆ページ数:83
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・バイオ
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、強皮症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、強皮症治療薬の世界市場規模及び予測、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。
【レポートの概要】

About Scleroderma Treatment
Scleroderma is an autoimmune disorder, which is a condition when body’s tissues get attacked by the immune system. The term scleroderma is defined as the hardening of the skin; however, it is much more than the skin disorder. The disease is characterized by microvascular injury and fibrosis in the affected organs.

Technavio’s analysts forecast the global scleroderma treatment market to grow at a CAGR of 7.02% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global scleroderma treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Scleroderma Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Pfizer

[Other prominent vendors]
• Amgen
• Bayer AG
• Boehringer Ingelheim
• Biogen
• CELGENE
• Corbus Pharmaceuticals
• Johnson & Johnson
• Merck
• Novartis
• Sanofi

[Market driver]
• High unmet medical needs
• For a full, detailed list, view our report

[Market challenge]
• Unknown pathogenesis of the disorder
• For a full, detailed list, view our report

[Market trend]
• Partnerships and strategic alliances
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【レポートの目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline
• Scleroderma disease overview
• Market landscape
• Market overview
• Five forces analysis

PART 05: Pipeline landscape

PART 06: Market segmentation by drug class
• Anti-inflammatory drugs
• Immunosuppressants
• Others
• PDE5 inhibitors
• Calcium channel blockers

PART 07: Geographical segmentation
• Scleroderma treatment market in Americas
• Scleroderma treatment market in EMEA
• Scleroderma treatment market in APAC

PART 08: Decision framework

PART 09: Drivers and challenges
• Market drivers
• Market challenges

PART 10: Market trends
• Partnerships and strategic alliances
• Introduction of stem cells in scleroderma treatment
• Advent of novel therapies

PART 11: Vendor landscape
• Competitive scenario

PART 12: Key vendor analysis
• AstraZeneca
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Pfizer
• Other prominent vendors

PART 13: Appendix
• List of abbreviations

[List of Exhibits] Exhibit 01: Types of scleroderma
Exhibit 02: Global scleroderma treatment market snapshot
Exhibit 03: Global scleroderma treatment market 2016-2021 ($ millions)
Exhibit 04: Opportunity analysis in global scleroderma treatment market
Exhibit 05: Five forces analysis
Exhibit 06: Number of pipeline molecules by vendors at various phases
Exhibit 07: Key clinical trials
Exhibit 08: Global scleroderma treatment market by drug class
Exhibit 09: Side effects associated with anti-inflammatory drug class
Exhibit 10: Global scleroderma anti-inflammatory drugs market 2016-2021 ($ millions)
Exhibit 11: Drivers and challenges of anti-inflammatory drugs
Exhibit 12: Side effects associated with immunosuppressants
Exhibit 13: Global scleroderma immunosuppressants market 2016-2021 ($ millions)
Exhibit 14: Drivers and challenges of immunosuppressants
Exhibit 15: Global scleroderma treatment market by others drug class 2016-2021 ($ millions)
Exhibit 16: Major drug classes included in the others segment
Exhibit 17: Side effects associated with PDE5 inhibitors
Exhibit 18: Global scleroderma PDE5 inhibitors market 2016-2021 ($ millions)
Exhibit 19: Drivers and challenges of PDE5 inhibitors
Exhibit 20: Side effects associated with calcium channel blockers
Exhibit 21: Global scleroderma calcium channel blockers market 2016-2021 ($ millions)
Exhibit 22: Drivers and challenges of calcium channel blockers
Exhibit 23: Global scleroderma treatment market segmentation based on geography 2016 and 2021 (%)
Exhibit 24: Global scleroderma treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 25: Market scenario in Americas
Exhibit 26: Scleroderma treatment market in Americas 2016-2021 ($ millions)
Exhibit 27: Market scenario in EMEA
Exhibit 28: Scleroderma treatment market in EMEA 2016-2021 ($ millions)
Exhibit 29: Market scenario in APAC
Exhibit 30: Scleroderma treatment market in APAC 2016-2021 ($ millions)
Exhibit 31: Promising new projects in scleroderma studies
Exhibit 32: Potential therapeutic targets involved in numerous studies for scleroderma
Exhibit 33: Strategic success factors of companies in global scleroderma treatment market
Exhibit 34: AstraZeneca: Key highlights
Exhibit 35: AstraZeneca: Strength assessment
Exhibit 36: AstraZeneca: Strategy assessment
Exhibit 37: AstraZeneca: Opportunity assessment
Exhibit 38: F. Hoffmann-La Roche: Key highlights
Exhibit 39: F. Hoffmann-La Roche: Strength assessment
Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 42: GlaxoSmithKline: Key highlights
Exhibit 43: GlaxoSmithKline: Strength assessment
Exhibit 44: GlaxoSmithKline: Strategy assessment
Exhibit 45: GlaxoSmithKline: Opportunity assessment
Exhibit 46: Pfizer: Key highlights
Exhibit 47: Pfizer: Strength assessment
Exhibit 48: Pfizer: Strategy assessment
Exhibit 49: Pfizer: Opportunity assessment



【掲載企業】

AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline, and Pfizer.

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[強皮症治療薬の世界市場2017-2021] (コード:IRTNTR13556)販売に関する免責事項を必ずご確認ください。
★調査レポート[強皮症治療薬の世界市場2017-2021]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆